Canon Medical Systems USA, Inc., FUJIFILM Corporation, and F. Hoffmann-La Roche Ltd Dominated the Global Thyroid Cancer Diagnostics Market in 2022

The Global Thyroid Cancer Diagnostics Market is expected to grow with a CAGR of 5.7% in the forecast period of 2023 to 2030. The years considered for the study are as mentioned below:  

Access Full Report at @ https://www.databridgemarketresearch.com/reports/global-thyroid-cancer-diagnostics-market

The global thyroid cancer diagnostics market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to a favorable market scenario.

Some of the major players in the global thyroid cancer diagnostics market are introducing a wide range of products and adopting strategic initiatives such as acquisitions, agreements, business expansions, approvals, and awards and recognitions into the market. This helps the companies maximize their sales with an enhanced product portfolio.

For instance,

• In January 2021, FUJIFILM Corporation announced opening of two new "NURA" health screening centers focusing on cancer and lifestyle diseases screening in India. The new NURA centers opened in Gurugram on July 21, 2022, and will open in Mumbai in September. This will help the company expand its business and increase public exposure to its health

Canon Medical Systems USA, Inc. is the dominating player in the global Thyroid cancer diagnostics market. The other key players existing in the market are Quest Diagnostics Incorporated Illumina, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN S.P.A., Merck KGaA, Hologic, Myriad, Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd., and SternMed GmbH. among others.

Canon Medical Systems USA, Inc.

Canon Medical Systems USA, Inc. was founded in 1933 and is headquartered in California, U.S. It has private ownership. The company focuses on delivering innovative imaging solutions and services through our Made for Life philosophy to improve the quality of life for all people. The company has product categories Angiography, Computed Tomography, Molecular Imaging, Magnetic Resonance, Ultrasound, X-ray, Healthcare IT, and Eye Care, out of which angiography is the market-focused category.

The company has a wide presence across North America.

FUJIFILM Corporation.

FUJIFILM Corporation was founded in 2006 and is headquartered in Tokyo, Japan. It has public ownership.

The company focuses on a wide range of business in the three fields of healthcare, materials and imaging through leveraging the expertise. The company has business segments such as Healthcare, Business Innovations, Materials, and Imaging, out of which healthcare is the market-focused segment. The product categories are Consumer Products, Healthcare Products, Business Products, and Others, out of which healthcare products are the market-focused category.

For instance,

• In January 2021, FUJIFILM Corporation announced opening of two new "NURA" health screening centers focusing on cancer and lifestyle diseases screening in India. The new NURA centers opened in Gurugram on July 21, 2022, and opened in Mumbai in September. This will help the company expand its business and increase public exposure to its health

The company has a wide presence across North America, Europe, the Middle East and Africa, Asia-Pacific, and South America. The subsidiaries of FUJIFILM Holdings Corporation are Fujifilm Irvine Scientific, Inc. (United States), Fujifilm Electronic Materials (United States), Fujifilm UK Limited (U.K.), and Black Photo Corporation (Canada), among others.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd was founded in 1896 and is headquartered in Rotkreuz, Switzerland. It has public ownership.

The company focuses on the development of innovative products and services that address the prevention, diagnosis, monitoring, screening, and treatment of diseases. The company has business segments such as Roche Pharma and Roche Diagnostics, out of which Roche Diagnostics is the market-focused segment. The product categories are Cardiology, Gynaecology, Infectious Disease, Neurology, and Oncology, out of which oncology is the market-focused category.

For instance,

• In August 2022, F. Hoffmann-La Roche Ltd announced the launch of the Digital LightCycler System, Roche's first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods. This has helped the company to increase its global presence in the market

The company has a wide presence across Asia-Pacific, Europe, the Middle East and Africa, and North America. The subsidiaries of F. Hoffmann-La Roche Ltd are Roche Austria GmbH, Roche Diagnostics GmbH (Austria), Roche Diabetes Care Austria GmbH (Austria), Roche Diabetes Care Austria GmbH (Austria), and MySugr GmbH, among others.